Revive Therapeutics Ltd. (CNSX: RVV)

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.

ISIN

CA7615161030

Listed since

Jul 12, 2013

Exchange

Canadian National Stock Exchange

Currency

CAD